secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001689375-23-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q1 net loss $6.7M, cash $411.6M; advancing Duchenne pipeline despite clinical hold
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $411.6M at March 31, 2023, up from $188.7M at Dec 31, 2022.
- Collaboration revenue from Vertex deal $25.3M in Q1; net loss improved to $6.7M from $21.7M in Q1 2022.
- Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; eligible for up to $485M milestones plus royalties.
- ENTR-601-44 IND on clinical hold with FDA; pursuing global healthy volunteer trial initiation in 2023.
- ENTR-601-45 selected as second Duchenne candidate; IND submission planned for Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/0001689375-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/trda-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer